Search
Showing results for "lung disease preterm"
Results of an innovative clinical trial led by Perth researchers have shown that the drug interferon could help reduce the spread of COVID-19 from a positive person to their household contacts, with the study helping to inform treatment options for a future pandemic.
The Wal-yan Respiratory Research Centre's dedicated team members, along with special guests, embarked on a journey to Wadjemup (Rottnest Island) on 9 and 10 November.
We are excited to announce the winners of our inaugural Illuminate Awards
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
To investigate the physicochemical compatibility of caffeine citrate and caffeine base injections with 43 secondary intravenous drugs used in Neonatal Intensive Care Unit settings.
Preterm infants are at a higher risk of hospitalisation following discharge from the hospital after birth.
Paediatric Physiotherapist
Amber Mum of four, Ethany, Xavier, Imogen and Adison. Co-founder of Tiny Sparks WA, Chair of Preterm Community Reference Group, Wal-yan Respiratory
Find out about the research outputs for the Development Pathways Project, and see the published research outcomes.
Multidrug-resistant tuberculosis is uncommon in Australia